Kindeva Appoints Daniel J. Speciale as the New Chief Financial Officer (CFO)

Mr. Speciale has nearly 20 years of financial leadership and deep healthcare and  pharmaceuticals. Most recently, Mr. Speciale served as Senior Vice President, Finance— Controller, and Chief Accounting Officer at Vantive, where he played a key role in establishing  financial strategy as the business separated from Baxter in a $3.8 billion sale to Carlyle. Previously, he held senior financial roles at Mallinckrodt, including Senior Vice President,  Finance and CFO of the Specialty Generics division, overseeing $800 million in annual revenue  while leading the controllership and investor relations functions. He began his career in the  assurance practice at PricewaterhouseCoopers LLP, and his expertise in financial leadership  across public and private companies makes him an asset to Kindeva's growth. 
Comunicato Precedente

next
Comunicato Successivo

next
ST. LOUIS, (informazione.it - comunicati stampa - salute e benessere)

Mr. Speciale has nearly 20 years of financial leadership and deep healthcare and  pharmaceuticals. Most recently, Mr. Speciale served as Senior Vice President, Finance— Controller, and Chief Accounting Officer at Vantive, where he played a key role in establishing  financial strategy as the business separated from Baxter in a $3.8 billion sale to Carlyle. Previously, he held senior financial roles at Mallinckrodt, including Senior Vice President,  Finance and CFO of the Specialty Generics division, overseeing $800 million in annual revenue  while leading the controllership and investor relations functions. He began his career in the  assurance practice at PricewaterhouseCoopers LLP, and his expertise in financial leadership  across public and private companies makes him an asset to Kindeva's growth. 

Mr. Speciale holds a Bachelor of Science in Accountancy and a Master of Accounting Science  degree from the Gies College of Business at the University of Illinois Urbana-Champaign.

Commenting on his appointment, Mr. Speciale said, "I look forward to joining Kindeva at such  a dynamic time in its journey. Financial discipline, strategic investment, and operational  efficiency are critical in today's evolving market. I look forward to joining the company and  working with the leadership team to drive sustainable growth and long-term success."

Kindeva is a leading global CDMO with vast expertise in drug delivery devices. Learn more  about their services here.

Kindeva Appoints Daniel J. Speciale as the New Chief Financial Officer (CFO)

About Kindeva Drug Delivery

At Kindeva, our purpose is clear: manufacturing more tomorrows for patients worldwide. By investing in the highest quality facilities, finished-dose CDMO solutions and analytical capabilities, we provide strategic value that extends beyond manufacturing. Our global network of 10 manufacturing and R&D facilities offers exceptional capabilities, including expanded aseptic fill finish capacity and next-generation green propellant technologies. We leverage our sterile injectable, pulmonary, nasal and dermal expertise to help meet the demands of today and deliver the possibilities of tomorrow.

 

Cision View original content to download multimedia:https://www.prnewswire.co.uk/news-releases/kindeva-appoints-daniel-j-speciale-as-the-new-chief-financial-officer-cfo-302415867.html

Ufficio Stampa

 PR Newswire (Leggi tutti i comunicati)
209 - 215 Blackfriars Road
LONDON United Kingdom

Allegati
Slide ShowSlide Show
Non disponibili